B-cell treatment in ANCA-associated vasculitis

Author:

Karras Alexandre123,Lazareth Hélène123,Chauvet Sophie124

Affiliation:

1. Nephrology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris

2. Univesité Paris Descartes

3. INSERM U970, Paris Cardiovascular Centre (PARCC)

4. INSERM UMRS 1138, Cordeliers Research Center, Complement and Diseases team, Paris, France

Abstract

AbstractThe pivotal role of B-cells in ANCA-associated vasculitis has been suggested by experimental data that demonstrate the direct pathogenicity of ANCAs. Rituximab (RTX), an anti-CD20 monoclonal antibody that targets B-cells, has proven its efficacy for induction of remission in severe ANCA vasculitis. RTX is equivalent to CYC for induction of remission, and is probably superior in relapsing patients. Long-term B cell depletion by prolonged RTX treatment has been shown to significantly reduce the relapse rate, when compared with AZA maintenance therapy. Biomarkers, such as B-cell subpopulations or ANCA monitoring, may help the clinician to determine the optimal dose and duration of RTX therapy.

Funder

University of Cambridge

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference40 articles.

1. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides;Jennette;Arthritis Rheum,2013

2. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis;van der Woude;Lancet,1985

3. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease;Jennette;Nat Rev Rheumatol,2014

4. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro;Falk;Proc Natl Acad Sci USA,1990

5. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells;Savage;Am J Pathol,1992

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3